Sonny Hsiao, Ph.D. of Acopedia shares his final thoughts on Acepodia Presents Preclinical Data on its Lead NK Cell Therapy Candidate ACE1702 at 2020 AACR Virtual Meeting II.
SAN FRANCISCO and TAIPEI, Taiwan, June 22, 2020 (GLOBE NEWSWIRE) — Acepodia, a biotechnology company developing cancer immunotherapy based on its innovative technology platform ACC (Antibody Cell Conjugation), today revealed preclinical data on ACE1702, a natural killer cell (NK cell) therapy being developed as a treatment for strong HER2-expressing tumours. The knowledge was discussed at the 2020 Virtual Annual Meeting II of the American Association for Cancer Research (AACR) in a digital poster session. ACE1702 is Acepodia 's lead candidate for off-the-shelf cell therapy and recently obtained investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA) to be tested in clinical trials under Phase 1. Details can be found below about the on-demand multimedia presentation:
Details of the presentation
Title: ACE1702: A potent, off-shelf product for cell therapy
2169 / 1 Abstract:
Session: PO.IM02.02-Cell Therapy Adoption 2
Date: 22 June 2020 to 9:00 a.m. -The 6:00 p.m. EDT-EDT
Strong tumors pose a major obstacle to existing cell therapies and constitute over 80 percent of new diagnosis of cancer. Sonny Hsiao, Ph.D., chief executive officer of Acepodia, said that our innovative approach to the production of cell therapy might potentially provide a versatile and cost-effective alternative with an improved potency that is required to effectively treat solid tumors. ACE1702 is our first clinical candidate to be established using our antibody-cell-conjugation technology that combines the antibody target specificity with our off-the-shelf natural killer cell line's anti-tumor ability. In this presentation of preclinical results, we were pleased to demonstrate the potential of ACE1702 to treat HER2-expressing solid tumors, and we look forward to promptly enrolling the first patient in our Phase 1 clinical trial.
Highlights from the presentation:
The poster presentation will highlight preclinical data on the leading clinical candidate of Acepodia ACE1702, a novel NK cell therapy developed using Acepodia 's proprietary antibody-cell-conjugation (ACC) technology in tandem with its powerful off-the-shelf NK cell line (oNK) for the treatment of solid HER2-expressing tumors. Main conclusions from the presentation include:
Trastuzumab, an anti-HER2 antibody, is effectively conjugated by the ACC platform to the surface of Acepodia 's proprietary oNK cells and confers HER2 specificity.
ACE1702 exhibits cytotoxicity at varying levels against several cancerous cell lines that express HER2.
ACE1702 displays high levels of intracellular IFNπ compared to oNK cells in the presence of human ovarian cancer cells (SK-OV-3 cells), suggesting increased involvement and cytotoxicity by activated oNK cells in contact with tumor cells.
Tumor development in the SK-OV-3 xenograft mouse model is suppressed by ACE1702.
Acepodia is a privately owned U.S.-Taiwan biotechnology corporation that reshapes the field of cell therapy through a versatile and integrated approach to biological design that focuses mainly oncology. The Company's platform is rooted in its patented natural off-the-shelf killer cell line (oNK) selected for its powerful anti-tumor action. Acepodia's drug discovery platform is designed to increase the tumor affinity of oNK cells through both chimeric antigen receptor technology and its specific ACC (Antibody Cell-Conjugation) technology, which connects tumor targeting antibodies to the oNK cell surface.